About KRONOX Lab Sciences
KRONOX Lab Sciences is a publicly listed company based in Vadodara (India) founded in 2008. Manufacturer of high purity fine chemicals, specializing in chemical synthesis and analysis. The company has 71 employees. Its Indian entity Kronox Lab Sciences Limited reported revenue of ₹106 Cr. KRONOX Lab Sciences offers products and services including Bulk Reagents, ACS Reagents, Phosphates, EDTA Derivatives, and Ultra High Purity Chemicals. Its focus areas include Chemicals and Materials, Diversified Chemicals and Diversified.
Company details
KRONOX Lab Sciences was established in 2008 in Vadodara, India, within the chemicals sector. Operations center on the production of high purity fine chemicals, including synthesis and purification processes for inorganic products. Analytical services are also provided to support quality control. The company maintains its headquarters and manufacturing facilities in Vadodara, serving industrial needs in specialized chemical applications.
- Headquarters Vadodara, India
- Employees 71
- Stage Public
- SectorsChemicals & Materials
- Website kronoxlabsciences.com
- Social LinkedIn
- Legal Name Kronox Lab Sciences Limited
- Market Cap₹718 Cr
KRONOX · NSE
- Share Price₹190.24
-1.69% today
- Revenue₹101 Cr
FY 2025-26 · +1.0% YoY
- EBITDA₹34.27 Cr
Margin 33.9%
- Net Profit₹27.60 Cr
FY 2025-26 · +8.4% YoY
- P/E (TTM)24.8x
P/B 5.5x
- ROE26.8%
ROCE 36.0%
- Debt / Equity0.01
Interest cover 0.3x
- Employee Count71
Associated legal entities of KRONOX Lab Sciences
KRONOX Lab Sciences operates through Kronox Lab Sciences Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Kronox Lab Sciences Limited Listed CIN L24117GJ2008PLC055460 | Active | 18 Nov 2008 | Padra, Gujarat | ₹106 Cr | 70 | 9 | View details |
Products & Services of KRONOX Lab Sciences
KRONOX Lab Sciences offers a comprehensive portfolio of products and services, including Bulk Reagents, ACS Reagents, Phosphates, EDTA Derivatives, and Ultra High Purity Chemicals.
High purity reagents for industrial and lab use
American Chemical Society grade chemicals for quality applications
Chemicals used in food and pharmaceutical production
Derivatives for personal care and industrial processes
High-grade chemicals for precise scientific applications
Board of directors of Kronox Lab Sciences Limited (KRONOX Lab Sciences)
Kronox Lab Sciences Limited is the primary company behind KRONOX Lab Sciences. The board of Kronox Lab Sciences Limited currently have 6 directors; the longest-serving is Anuradha Suneet Maheshwari, appointed in 2026. 5 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Anuradha Suneet Maheshwari DIN 02689682 | Additional Director | 29 Sep 2026 | 1 mo | Kronox Lab Sciences Limited |
| Dhananjay Vishnu Tapasvi DIN 03309900 | Additional Director | 29 Sep 2026 | 1 mo | Kronox Lab Sciences Limited |
| Amit Kumar Sharma DIN 10464060 | Additional Director | 29 Sep 2026 | 1 mo | Kronox Lab Sciences Limited |
| Sunil Malhotra DIN 00361641 | Additional Director | 29 Sep 2026 | 1 mo | Kronox Lab Sciences Limited |
| Harsh Malhotra DIN 10785742 | Additional Director | 29 Sep 2026 | 1 mo | Kronox Lab Sciences Limited |
| Suresh Kalra DIN 02833715 | Managing Director | 29 Sep 2026 | 1 mo | Kronox Lab Sciences Limited |
People of KRONOX Lab Sciences
1 people are tracked at KRONOX Lab Sciences (1 in leadership); the tracked headcount is 71.
| Name | Role | Group |
|---|---|---|
| Managing Director | Leadership |
Complete people profiles for KRONOX Lab Sciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of KRONOX Lab Sciences
KRONOX Lab Sciences is a publicly listed company on the NSE with ticker symbol KRONOX in India, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 Jun 2024
- Listed onBSE: 544187 · NSE: KRONOX
- Listed entityKronox Lab Sciences Limited
- Exchange sectorProcess industries
- ISININE0ATZ01017
- Share price₹218.79 (+2.23% on the day) · 2026-10-14
- Market capitalisation₹797 Cr
- Price to earnings28.4
- EPS (diluted, trailing year)₹7.70
- Dividend yield0.23%
- Volume (last session)51,271
Financials of KRONOX Lab Sciences
Exchange-reported figures of Kronox Lab Sciences Limited, the listed company behind KRONOX Lab Sciences (NSE: KRONOX).
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 101 | 100 | 89.86 | 95.58 | 82.25 | 62.46 | 50.50 |
| Revenue growth | +1.0% | +11.5% | -6.0% | +16.2% | +31.7% | +23.7% | - |
| EBITDA | 34.27 | 33.12 | 28.33 | 21.71 | 19.69 | 14.80 | 11.71 |
| EBITDA margin | +33.9% | +33.1% | +31.5% | +22.7% | +23.9% | +23.7% | +23.2% |
| Profit before tax | 37.30 | 34.27 | 28.62 | 22.04 | 18.34 | 13.22 | 11.74 |
| Net profit | 27.60 | 25.47 | 21.36 | 16.39 | 13.59 | 9.71 | 8.60 |
| Net profit margin | +27.3% | +25.4% | +23.8% | +17.2% | +16.5% | +15.6% | +17.0% |
| EPS (₹) | 7.45 | 6.86 | 5.75 | 4.42 | 565.44 | 403.73 | 343.75 |
| Balance sheet | |||||||
| Total assets | 118 | 90.13 | 66.32 | 45.24 | 44.23 | 30.61 | 23.40 |
| Net worth | 116 | 90.10 | 66.30 | 44.75 | 40.35 | 26.81 | 23.34 |
| Total debt | 1.61 | 0.00 | 0.00 | 0.00 | 3.36 | 3.62 | 0.03 |
| Cash & bank | 48.74 | 36.68 | 3.64 | 3.56 | 2.81 | 2.05 | 2.48 |
| Net working capital | 69.09 | 54.60 | 38.93 | 25.38 | 31.60 | 19.17 | 16.27 |
| Cash flow | |||||||
| Cash from operations | 23.89 | 30.70 | 17.42 | 19.67 | 9.02 | 11.31 | 4.48 |
| Cash from investing | (23.82) | (28.39) | (17.31) | (6.60) | (7.60) | (2.96) | (3.92) |
| Cash from financing | (0.36) | (1.85) | 0.00 | (13.40) | (0.67) | (7.10) | (0.21) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.83 | 28.39 | 26.13 | 25.27 | 25.53 | 24.29 | 26.13 | 24.01 |
| Revenue growth (YoY) | +5.1% | +16.9% | 0.0% | +5.3% | +2.7% | -3.6% | - | - |
| Other income | 0.87 | 1.30 | 2.15 | 1.13 | 1.04 | 0.87 | 0.91 | 0.82 |
| Total expenses | 18.40 | 19.39 | 16.61 | 17.25 | 16.89 | 16.32 | 18.38 | 15.65 |
| EBITDA | 8.43 | 9.00 | 9.52 | 8.02 | 8.64 | 7.97 | 7.75 | 8.36 |
| EBITDA margin | +31.4% | +31.7% | +36.4% | +31.7% | +33.8% | +32.8% | +29.7% | +34.8% |
| Depreciation | 0.49 | 0.45 | 0.66 | 0.52 | 0.47 | 0.40 | 0.35 | 0.36 |
| Interest | 0.08 | 0.03 | 0.04 | 0.04 | 0.04 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 8.73 | 9.82 | 10.97 | 8.59 | 9.17 | 8.44 | 8.31 | 8.82 |
| Tax | 2.29 | 2.51 | 2.96 | 2.01 | 2.50 | 2.17 | 2.00 | 2.30 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.83 | 28.39 | 26.13 | 25.27 | 25.53 | 24.29 | 26.13 | 24.01 |
| Revenue growth (YoY) | +5.1% | +16.9% | 0.0% | +5.3% | +2.7% | -3.6% | - | - |
| Other income | 0.87 | 1.30 | 2.15 | 1.13 | 1.04 | 0.87 | 0.91 | 0.82 |
| Total expenses | 18.40 | 19.39 | 16.61 | 17.25 | 16.89 | 16.32 | 18.38 | 15.65 |
| EBITDA | 8.43 | 9.00 | 9.52 | 8.02 | 8.64 | 7.97 | 7.75 | 8.36 |
| EBITDA margin | +31.4% | +31.7% | +36.4% | +31.7% | +33.8% | +32.8% | +29.7% | +34.8% |
| Depreciation | 0.49 | 0.45 | 0.66 | 0.52 | 0.47 | 0.40 | 0.35 | 0.36 |
| Interest | 0.08 | 0.03 | 0.04 | 0.04 | 0.04 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 8.73 | 9.82 | 10.97 | 8.59 | 9.17 | 8.44 | 8.31 | 8.82 |
| Tax | 2.29 | 2.51 | 2.96 | 2.01 | 2.50 | 2.17 | 2.00 | 2.30 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 101 | 100 | 89.86 | 95.58 | 82.25 | 62.46 | 50.50 |
| Revenue growth | +1.0% | +11.5% | -6.0% | +16.2% | +31.7% | +23.7% | - |
| Other income | 5.19 | 2.53 | 1.58 | 1.92 | 1.09 | 0.78 | 1.07 |
| Total expenses | 66.95 | 67.07 | 61.53 | 73.87 | 62.56 | 47.66 | 38.79 |
| Employee cost | 3.44 | 2.95 | 2.50 | 1.93 | 1.65 | 1.49 | 1.20 |
| EBITDA | 34.27 | 33.12 | 28.33 | 21.71 | 19.69 | 14.80 | 11.71 |
| EBITDA margin | +33.9% | +33.1% | +31.5% | +22.7% | +23.9% | +23.7% | +23.2% |
| Depreciation | 2.05 | 1.38 | 1.29 | 1.50 | 2.03 | 1.98 | 0.96 |
| Interest | 0.11 | 0.00 | 0.00 | 0.09 | 0.41 | 0.38 | 0.08 |
| Profit before tax | 37.30 | 34.27 | 28.62 | 22.04 | 18.34 | 13.22 | 11.74 |
| Tax | 9.64 | 8.80 | 7.26 | 5.64 | 4.73 | 3.49 | 3.14 |
| Net profit | 27.60 | 25.47 | 21.36 | 16.39 | 13.59 | 9.71 | 8.60 |
| Net profit margin | +27.3% | +25.4% | +23.8% | +17.2% | +16.5% | +15.6% | +17.0% |
| EPS (₹) | 7.45 | 6.86 | 5.75 | 4.42 | 565.44 | 403.73 | 343.75 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 37.10 | 37.10 | 37.10 | 37.10 | 0.24 | 0.24 | 0.25 |
| Reserves & surplus | 79.02 | 53.00 | 29.20 | 7.65 | 40.11 | 26.57 | 23.09 |
| Shareholders' funds (net worth) | 116 | 90.10 | 66.30 | 44.75 | 40.35 | 26.81 | 23.34 |
| Secured loans | 1.61 | 0.00 | 0.00 | 0.00 | 0.17 | 0.01 | 0.03 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 3.19 | 3.61 | 0.00 |
| Total debt | 1.61 | 0.00 | 0.00 | 0.00 | 3.36 | 3.62 | 0.03 |
| Total liabilities | 118 | 90.13 | 66.32 | 45.24 | 44.23 | 30.61 | 23.40 |
| Assets | |||||||
| Gross block | 42.88 | 40.31 | 37.48 | 25.69 | 21.74 | 17.71 | 12.19 |
| Net block | 28.73 | 27.86 | 26.41 | 15.91 | 11.30 | 9.19 | 5.54 |
| Capital work in progress | 0.88 | 0.76 | 0.49 | 0.00 | 0.00 | 0.40 | 0.00 |
| Investments | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Inventories | 8.37 | 6.37 | 9.25 | 9.17 | 7.51 | 5.49 | 5.04 |
| Sundry debtors | 21.19 | 19.89 | 17.65 | 18.55 | 25.80 | 15.44 | 15.19 |
| Cash & bank balances | 48.74 | 36.68 | 3.64 | 3.56 | 2.81 | 2.05 | 2.48 |
| Loans & advances | 0.55 | 0.36 | 16.06 | 2.90 | 8.04 | 3.23 | 4.39 |
| Total current assets | 78.85 | 63.30 | 46.60 | 34.18 | 44.16 | 26.21 | 27.10 |
| Total current liabilities | 9.76 | 8.70 | 7.67 | 8.80 | 12.56 | 7.04 | 10.83 |
| Net working capital | 69.09 | 54.60 | 38.93 | 25.38 | 31.60 | 19.17 | 16.27 |
| Total assets | 118 | 90.13 | 66.32 | 45.24 | 44.23 | 30.61 | 23.40 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 3.04 | 2.59 | 2.48 | 2.81 | 2.05 | 0.79 | 0.44 |
| Net cash from operating activities | 23.89 | 30.70 | 17.42 | 19.67 | 9.02 | 11.31 | 4.48 |
| Net cash from investing activities | (23.82) | (28.39) | (17.31) | (6.60) | (7.60) | (2.96) | (3.92) |
| Net cash from financing activities | (0.36) | (1.85) | 0.00 | (13.40) | (0.67) | (7.10) | (0.21) |
| Net change in cash | (0.29) | 0.45 | 0.10 | (0.33) | 0.76 | 1.26 | 0.35 |
| Closing cash | 48.74 | 36.68 | 3.64 | 3.56 | 2.81 | 2.05 | 2.48 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +1.0% | +11.5% | -6.0% | +16.2% | +31.7% | +23.7% | - |
| EBITDA growth | +3.5% | +16.9% | +30.5% | +10.3% | +33.0% | +26.4% | - |
| PBT growth | +8.8% | +19.7% | +29.9% | +20.2% | +38.7% | +12.6% | +9997.0% |
| Net income growth | +8.4% | +19.2% | +30.3% | +20.6% | +40.0% | +12.9% | - |
| Revenue CAGR (3Y) | +1.9% | +6.8% | +12.9% | +23.7% | - | - | - |
| EBITDA CAGR (3Y) | +16.4% | +18.9% | +24.2% | +22.9% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +27.3% | +25.4% | +23.8% | +17.2% | +16.6% | +15.6% | +17.0% |
| Return on capital employed | +36.0% | +43.8% | +51.3% | +50.2% | +50.2% | +50.4% | +50.5% |
| Return on net worth | +26.8% | +32.6% | +38.5% | +39.1% | +40.6% | +38.8% | +36.8% |
| Debt / equity | 0.01 | 0.00 | 0.00 | 0.04 | 0.10 | 0.07 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.03 | 0.07 | 0.05 | 0.00 |
| Interest cover | 0.34 | 0.00 | 0.00 | 0.45 | 2.32 | 2.96 | 0.74 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 2.43 | 2.58 | 2.85 | 4.03 | 4.17 | 4.18 | 4.14 |
| Inventory turnover | 13.73 | 12.83 | 9.76 | 11.46 | 12.65 | 11.86 | 10.02 |
| Debtors turnover | 4.93 | 5.34 | 4.96 | 4.31 | 3.99 | 4.08 | 3.32 |
| EPS (₹) | 7.45 | 6.86 | 5.75 | 4.42 | 565.44 | 403.73 | 343.75 |
| Dividend per share (₹) | 0.50 | 0.50 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 31.30 | 24.28 | 17.87 | 12.06 | 1,674.40 | 1,112.61 | 933.52 |
Web traffic of KRONOX Lab Sciences
The website of KRONOX Lab Sciences (kronoxlabsciences.com) receives about 1.2K visits a month.
- Monthly visits1.2K
▲ 16.8% vs previous month
Top companies in Core & Diversified Chemicals
3 companies that operate in the same segment as KRONOX Lab Sciences (Core & Diversified Chemicals) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of fertilizers, industrial chemicals, crop nutrition products, and real estate | 1979 | Pune, Maharashtra, India | USD 1.21 B | 1,020 | ||
Specialty chemicals are manufactured through integrated R&D and production processes. | 2023 | Bengaluru, Karnataka, India | USD 72.97 M | USD 23.86 M | ||
Manufactures coal tar and basic industrial chemicals. | 1987 | Kolkata, West Bengal, India | USD 24 M | USD 515.01 M | 1,161 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kronox Lab Sciences
Complete news archive for KRONOX Lab Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about KRONOX Lab Sciences
KRONOX Lab Sciences was founded in 2008.
KRONOX Lab Sciences is headquartered in Vadodara, India. It is registered at Vadodara, Gujarat, India.
KRONOX Lab Sciences has 71 employees.
The primary company behind KRONOX Lab Sciences, Kronox Lab Sciences Limited, reported revenue of ₹106 Cr for FY 2026, up 1% year on year.
KRONOX Lab Sciences was established in 2008 in Vadodara, India, within the chemicals sector. Operations center on the production of high purity fine chemicals, including synthesis and purification processes for inorganic products. Analytical services are also provided to support quality control. The company maintains its headquarters and manufacturing facilities in Vadodara, serving industrial needs in specialized chemical applications.
KRONOX Lab Sciences offers Bulk Reagents, ACS Reagents, Phosphates, EDTA Derivatives, and Ultra High Purity Chemicals.
Yes, KRONOX Lab Sciences is publicly traded on NSE under the ticker symbol KRONOX.
KRONOX Lab Sciences operates through Kronox Lab Sciences Limited.
The legal entities of KRONOX Lab Sciences currently have 8 directors, including Nikhil Goswami, Anuradha Suneet Maheshwari, Dhananjay Vishnu Tapasvi and others.